Gastric Motility Disorder Drug Market Size, Growth, Report By 2032

Published Date : 04 Sep 2023

The global gastric motility disorder drug market from 2023 to 2032, provides a comprehensive overview of the industry, market segmentation based on a variety of criteria, and the current vendor landscape.

Gastric Motility Disorder Drug Market Size and Growth Rate From 2023 To 2032

The market for global gastric motility disorder drugs grew throughout the historical period as a result of changes in lifestyle, robust economic growth in emerging economies, rising pharmaceutical R&D spending, rising insurance coverage, ageing population patterns, and rising healthcare costs. Drug patent expirations, difficulties resulting from legislative changes, limited access to healthcare, and a growing preference for biological methods all had an impact on the market.

Market Overview:

The diseases that affect the gastrointestinal system are referred to as gastrointestinal diseases. Heartburn, inflammatory bowel disorders (IBD), inflammatory bowel syndrome (IBS), diarrhea, and constipation are a few common digestive issues. Gastrointestinal disorders are a major consumer of and spender on health care. Over 9 million people worldwide have IBD, according to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA). IBD is becoming more common, which can be attributed to poor dietary decisions, such as consuming a lot of trans fats and ultra-processed foods.

The prevalence of diseases is predicted to rise as the population ages. The GI disorders, which include ulcerative colitis, Crohn's disease, and inflammatory bowel illnesses, are widespread, chronic inflammatory conditions that afflict a large portion of the global population. This is brought on by a sedentary lifestyle, alterations in nutritional preferences, stress, and other elements. IBS has become more common and more common in the world over the past few decades. IBS is the most prevalent functional gastrointestinal illness, with a prevalence rate of 10-15% worldwide, according to the International Foundation for Gastrointestinal Disorders, Inc. It is also among the most typical ailments that prompt a trip to the doctor. In the US, there are between 2.5 to 3.4 million doctor visits for IBS each year.

Regional Insight:

In terms of revenue share, North America dominated the world market in 2022. Due to variables like the high prevalence of chronic diseases, the existence of important pharmaceutical businesses, and the accessibility of cutting-edge treatment choices, the region is predicted to maintain its dominance over the projected period. Additionally, it is predicted that regional growth would be fueled by rising demand for new-generation pharmaceuticals because of their enhanced efficacy and safety features during the projected period.

The Asia Pacific region is anticipated to experience profitable growth over the course of the forecast period as a result of increasing patient awareness of available treatments and rising healthcare spending by governments in many nations, including China and India. These are just a few of the factors that can be used to explain the region's rapid market expansion.

Gastric Motility Disorder Drug Market Report Scope:

Report Coverage Details
Fastest Growing Market Asia Pacific
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Report Highlight:

  • By Type, it is divided into conditions like gastroesophageal reflux disease and inflammatory bowel illnesses. Inflammatory bowel illnesses are anticipated to see the highest CAGR over the course of the projection period, while the category for inflammatory ulcerative colitis retained the largest market share in 2022.
  • By Application, the market is divided into hospital pharmacies, home clinics, and other segments based on the distribution channel. The global gastric motility disorder medicine market was split, with hospital pharmacies making up the greatest portion. In the segmented global gastric motility disorder drug market going forward, home clinics are anticipated to develop at the fastest rate.

Market Dynamic:


Increase in the prevalence of GI disorders

IBD is the most prevalent functional gastrointestinal illness, with a prevalence rate of 10-15% worldwide, according to the International Foundation for Gastrointestinal Disorders, Inc. It is also among the most typical ailments that prompt a trip to the doctor. In the US, there are between 2.5–3.4 million doctor visits per year for IBD. IBD is thought to cost roughly US$ 21 billion yearly in direct medical costs and indirect costs related to lost productivity and absenteeism from work. Furthermore, IBD cases have increased globally during the past few years. IBD, also known as ulcerative colitis and Crohn's disease, is a persistent inflammation of the gastrointestinal tract.


Strict regulations and technological challenges affect the growth of this market

The licensing and marketing of drug supplies and equipment are subject to stringent regulations set by regulatory organizations in several nations. Technological obstacles include antibody cross-reactivity, false negatives, the low detection limits of the available antibodies, and others that also inhibit the growth of the gastric motility disorder drug market. Technicians that use gastric motility disorder drugs frequently run into design problems, like incorrect findings interpretation. Additionally, the clinical diagnostics business has been hampered by a long-standing dearth of skilled professionals


Increased development and research activity

This demand is mostly driven by the global increase in interest in the research activities associated to drug development. Also, these illnesses are highly common in the elderly, and as the geriatric population rises, so does the demand for these medications. The global gastric motility disorder drug market is also growing as a result of changing diets, bad eating habits, and stress levels. The treatments used to treat these issues are constantly evolving, and this will lead to significant growth in the gastric motility disorder medications market throughout the ensuing years.

The prevalence of gastrointestinal illnesses is extremely high worldwide, and there are many different drugs and therapies that can be used to treat them. Proper drug delivery is one such approach, and as a result, a distinct global market for gastrointestinal pharmaceuticals has emerged. This element is probably going to help the global market for gastric motility disorder drugs grow in the years to come.

Recent and Development:

  • Pizensy (lactitol) was given the go-ahead by the US Food and Drug Administration (FDA) in March 2020 for the therapy of chronic idiopathic constipation (CIC) in adults. Osmotic laxatives like penny function by generating an inflow of liquid into the small intestine, which then has a laxative effect on the colon.
  • The US Food and Drug Administration (FDA) approved Blueprint Medicines Corporation's Ayvakit (avapritinib) in January 2020 for the treatment of adults with gastrointestinal stromal tumours that are metastatic (cancer cells have spread to other parts of the body) or unresectable (cannot be removed through surgery) (GIST). Once more, on May 20, Deciphera Pharmaceuticals Inc.'s Qinlock (ripretinib) tablets won FDA approval as the first novel medication explicitly authorised as a fourth-line treatment for advanced gastrointestinal stromal tumour (GIST).

Key Market Player:

  • Abbott
  • Janssen Pharmaceuticals NV
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Gilead Sciences, Inc.
  • Biogen
  • Organon Group of Companies 
  • AbbVie Inc.
  • AstraZeneca
  • Salix Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Bayer AG

Market Segmentation:

By Type

  • Velusetrag
  • Ipamorelin
  • TD-8954
  • Others

By Application

  • Hospital
  • Clinic
  • Home Use

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333